1707

Grape King BioTWSE:1707 Stock Report

Market Cap

NT$24.1b

7D

-0.3%

1Y

-9.7%

Updated

17 Sep, 2021

Data

Company Financials +
1707 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance2/6
Financial Health6/6
Dividends3/6

1707 Overview

Grape King Bio Ltd produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy foods in Taiwan, China, and internationally.

Price History & Performance

Summary of all time highs, changes and price drops for Grape King Bio
Historical stock prices
Current Share PriceNT$162.50
52 Week HighNT$160.50
52 Week LowNT$190.50
Beta0.27
1 Month Change-1.22%
3 Month Change-3.56%
1 Year Change-9.72%
3 Year Change-22.25%
5 Year Change-37.98%
Change since IPO156.92%

Recent News & Updates

Apr 06
Grape King Bio (TPE:1707) Knows How To Allocate Capital

Grape King Bio (TPE:1707) Knows How To Allocate Capital

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...

Mar 22
Here's Why Grape King Bio (TPE:1707) Can Manage Its Debt Responsibly

Here's Why Grape King Bio (TPE:1707) Can Manage Its Debt Responsibly

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Shareholder Returns

1707TW Personal ProductsTW Market
7D-0.3%-0.8%-0.2%
1Y-9.7%-14.0%33.6%

Return vs Industry: 1707 exceeded the TW Personal Products industry which returned -14% over the past year.

Return vs Market: 1707 underperformed the TW Market which returned 33.6% over the past year.

Price Volatility

Is 1707's price volatile compared to industry and market?
1707 volatility
1707 Beta0.27
Industry Beta0.59
Market Beta1

Stable Share Price: 1707 is less volatile than 75% of TW stocks over the past 3 months, typically moving +/- 2% a week.

Volatility Over Time: 1707's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1969n/an/ahttps://www.grapeking.com.tw

Grape King Bio Ltd produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy foods in Taiwan, China, and internationally. It operates through Multi-Level Marketing, Distributors, and Original Design Manufacturer/Original Equipment Manufacturer (ODM/OEM) segments. The company offers mushroom mycelium products, such as ganoderma lucidum, agaricus blazei, antrodia cinnamomea, cordyceps sinensis, and coriolus versicolor; probiotics, including enterococcus, bifidobacterium, lactobacillus, pediococcus, streptococcus, saccharomyces, and clostridium; and enzymes.

Grape King Bio Fundamentals Summary

How do Grape King Bio's earnings and revenue compare to its market cap?
1707 fundamental statistics
Market CapNT$24.07b
Earnings (TTM)NT$1.28b
Revenue (TTM)NT$9.39b

18.8x

P/E Ratio

2.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
1707 income statement (TTM)
RevenueNT$9.39b
Cost of RevenueNT$1.80b
Gross ProfitNT$7.59b
ExpensesNT$6.31b
EarningsNT$1.28b

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)9.06
Gross Margin80.87%
Net Profit Margin13.67%
Debt/Equity Ratio2.1%

How did 1707 perform over the long term?

See historical performance and comparison

Dividends

3.9%

Current Dividend Yield

71%

Payout Ratio

Valuation

Is Grape King Bio undervalued compared to its fair value and its price relative to the market?

20.1%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 1707 (NT$162.5) is trading below our estimate of fair value (NT$203.26)

Significantly Below Fair Value: 1707 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 1707 is poor value based on its PE Ratio (18.8x) compared to the TW Personal Products industry average (15x).

PE vs Market: 1707 is poor value based on its PE Ratio (18.8x) compared to the TW market (16.4x).


Price to Earnings Growth Ratio

PEG Ratio: 1707 is poor value based on its PEG Ratio (2x)


Price to Book Ratio

PB vs Industry: 1707 is overvalued based on its PB Ratio (2.6x) compared to the TW Personal Products industry average (2x).


Future Growth

How is Grape King Bio forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

9.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1707's forecast earnings growth (9.6% per year) is above the savings rate (0.8%).

Earnings vs Market: 1707's earnings (9.6% per year) are forecast to grow faster than the TW market (8.6% per year).

High Growth Earnings: 1707's earnings are forecast to grow, but not significantly.

Revenue vs Market: 1707's revenue (6.5% per year) is forecast to grow slower than the TW market (9.5% per year).

High Growth Revenue: 1707's revenue (6.5% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 1707's Return on Equity is forecast to be low in 3 years time (16.3%).


Past Performance

How has Grape King Bio performed over the past 5 years?

0.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1707 has high quality earnings.

Growing Profit Margin: 1707's current net profit margins (13.7%) are lower than last year (14.1%).


Past Earnings Growth Analysis

Earnings Trend: 1707's earnings have grown by 0.4% per year over the past 5 years.

Accelerating Growth: 1707's earnings growth over the past year (0.3%) is below its 5-year average (0.4% per year).

Earnings vs Industry: 1707 earnings growth over the past year (0.3%) underperformed the Personal Products industry 17.9%.


Return on Equity

High ROE: 1707's Return on Equity (18.6%) is considered low.


Financial Health

How is Grape King Bio's financial position?


Financial Position Analysis

Short Term Liabilities: 1707's short term assets (NT$4.5B) exceed its short term liabilities (NT$2.9B).

Long Term Liabilities: 1707's short term assets (NT$4.5B) exceed its long term liabilities (NT$433.2M).


Debt to Equity History and Analysis

Debt Level: 1707's debt to equity ratio (2.1%) is considered satisfactory.

Reducing Debt: 1707's debt to equity ratio has reduced from 53% to 2.1% over the past 5 years.

Debt Coverage: 1707's debt is well covered by operating cash flow (1200.7%).

Interest Coverage: 1707's interest payments on its debt are well covered by EBIT (609.6x coverage).


Balance Sheet


Dividend

What is Grape King Bio current dividend yield, its reliability and sustainability?

3.94%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 1707's dividend (3.94%) is higher than the bottom 25% of dividend payers in the TW market (1.94%).

High Dividend: 1707's dividend (3.94%) is low compared to the top 25% of dividend payers in the TW market (5.25%).


Stability and Growth of Payments

Stable Dividend: Whilst dividend payments have been stable, 1707 has been paying a dividend for less than 10 years.

Growing Dividend: 1707's dividend payments have increased, but the company has only paid a dividend for 7 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (70.6%), 1707's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: 1707's dividends in 3 years are forecast to be covered by earnings (68.2% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.8yrs

Average management tenure


CEO

Grape King Bio has no CEO, or we have no data on them.


Leadership Team

Experienced Management: 1707's management team is seasoned and experienced (6.8 years average tenure).


Board Members

Experienced Board: 1707's board of directors are considered experienced (6.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.9%.


Top Shareholders

Company Information

Grape King Bio Ltd's employee growth, exchange listings and data sources


Key Information

  • Name: Grape King Bio Ltd
  • Ticker: 1707
  • Exchange: TWSE
  • Founded: 1969
  • Industry: Personal Products
  • Sector: Household
  • Market Cap: NT$24.072b
  • Shares outstanding: 148.14m
  • Website: https://www.grapeking.com.tw

Number of Employees


Location

  • Grape King Bio Ltd
  • Jinling Road
  • No. 402, Section 2
  • Taoyuan City
  • 324
  • Taiwan

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/17 15:37
End of Day Share Price2021/09/17 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.